EXECUTIVE INTERVIEWS

  • A Look Inside J&J’s Partnering & Innovation-Building Model
    A Look Inside J&J’s Partnering & Innovation-Building Model

    Joaquin Duato, vice chairman of J&J’s executive committee, discusses how the company’s partnering and innovation-building model has evolved — and why.

  • BeiGene Exec Talks Candidly About Quality, Compliance, And Outsourcing
    BeiGene Exec Talks Candidly About Quality, Compliance, And Outsourcing

    Outsourced Pharma Chief Editor Louis Garguilo continues his coverage of the current state of China pharma manufacturing by interviewing Diana Francis, VP of quality and compliance for BeiGene.

  • Navigating The Turbulent Waters From Discovery To Clinical
    Navigating The Turbulent Waters From Discovery To Clinical

    “A partnering deal with a bigger pharma company would certainly help us through [the Phase 3] process,” explains Jeff Davidson, CEO of Keystone Nano, a company that develops nanoparticles that target solid tumors by going after cancer cells and leaving the normal cells intact.

  • How Halozyme’s First-Time CEO Financed Drug Development
    How Halozyme’s First-Time CEO Financed Drug Development

    “Making sure we had the money for staff and activities to build the business for the long-term was a key initial step,” explains Dr. Helen Torley, CEO of Halozyme Therapeutics.

  • Three “Others” Of The New Oncology
    Three “Others” Of The New Oncology

    An in-depth look at three developers that exemplify the range of new approaches and alternatives in the IO combo space: Oncosec Medical, Heat Biologics, and Rexahn.

  • The Future Of Biopharma Hinges On The Ability To Manufacture
    The Future Of Biopharma Hinges On The Ability To Manufacture

    Industry experts answer questions around future biopharma manufacturing trends, challenges, technologies, performance metrics, risk mitigation, people, and outsourcing.

  • Forecasting Biopharma’s Financial Future
    Forecasting Biopharma’s Financial Future

    We connected with a collection of biopharma financial experts to get you prepared for JPM, BTS, and the BIO CEO & Investors Conference in the first quarter of 2019.

  • Is Biopharma Still Committed To Its Role In Public Health?
    Is Biopharma Still Committed To Its Role In Public Health?

    Biopharma executives in companies of all sizes share their views on whether the now dominant life sciences industry business model, with its focus on rare diseases affecting small patient populations, allows companies to meet their historical public-health obligation.

  • Oncology Studies Show Pharma The Future Of Clinical Trials
    Oncology Studies Show Pharma The Future Of Clinical Trials

    What does the future hold for oncology trials, which now comprise around 80 percent of all clinical research? We spoke to three experts who shared their insights into where the industry is headed in 2019 and beyond.

  • Prophecy & Prognostication 2.0 — A Charting Of Biopharma's Future
    Prophecy & Prognostication 2.0 — A Charting Of Biopharma's Future

    We asked multiple biopharma CEOs everything from which executives or companies they pay close attention to in and outside of their industry, to questions about geopolitical issues, tech trends, and everything in between.

  • Biopharma Supply Chains At Industry 4.0
    Biopharma Supply Chains At Industry 4.0

    To get to a full digital dialogue that includes everything from AI to blockchain to machine learning, drug sponsors and CDMOs alike will need to muster their resources to usher in what the rest of the world already calls Industry 4.0.

  • How Can The U.S. Government Take Ownership Of Biosimilars In 2019?
    How Can The U.S. Government Take Ownership Of Biosimilars In 2019?

    Though the FDA has outlined many promising efforts to help the U.S. biosimilar market grow, the biosimilar industry’s public comments reveal an increasing need for the U.S. government healthcare agencies to take even greater charge of biosimilar policy in 2019.

  • ARM Extends Its Reach
    ARM Extends Its Reach

    The ARM Foundation for Cell and Gene was launched in June, and it marks a new stage in development of the RM space as it moves from an early era or “promise” to one of fulfillment. Today, nearly 900 companies worldwide are developing RM therapies.

  • Liz Barrett — Novartis Oncology’s NextGen Leader
    Liz Barrett — Novartis Oncology’s NextGen Leader

    Liz Barrett recently sat down with Life Science Leader to share some of the formative experiences that shaped her into the leader she has become, including one of the most recent challenges she is embracing at Novartis.

More executive interviews

BEYOND THE PRINTED PAGE

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

More From Life Science Leader Blogs

@LIFESCILEADER1